Mivuxin (Noradrenaline Tartrate)

Noradrenaline tartrate, the active ingredient in Mivuxin, is a sympathomimetic presented as an intravenous solution for intravenous use. It is employed to raise blood pressure in acute settings such as severe hypotension, septic shock, and cardiac arrest, acting directly on vascular smooth muscle to increase systemic vascular resistance.

GNH USA supplies Mivuxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product complies with European Union regulatory standards and is distributed under strict quality‑assurance protocols.

Mivuxin is a vasopressor used in critical care to counteract profound circulatory failure.

- Hypotension: restores arterial pressure by inducing peripheral vasoconstriction in patients with severe low blood pressure. - Septic shock: supports hemodynamics by increasing systemic vascular resistance when fluid resuscitation alone is insufficient. - Cardiac arrest: provides immediate pressor support during advanced cardiac life support to improve coronary and cerebral perfusion.

Mivuxin may cause a range of adverse reactions that vary with dose, infusion rate, and patient condition.

Common Side Effects: - Tachycardia: rapid heart rate due to beta‑1 stimulation. - Headache: secondary to elevated blood pressure. - Anxiety or restlessness: central nervous system response. - Peripheral ischemia: reduced blood flow to extremities. - Extravasation injury: tissue damage if the solution leaks from the vein. - Nausea: gastrointestinal upset.

Serious or Rare Side Effects: - Myocardial ischemia: reduced coronary blood flow leading to chest pain. - Severe hypertension: excessive rise in blood pressure causing vascular injury. - Cardiac arrhythmias: potentially life‑threatening rhythm disturbances. - Tissue necrosis at infusion site: severe extravasation requiring surgical intervention. - Pulmonary edema: fluid accumulation in lungs due to increased afterload. - Limb gangrene: extreme peripheral vasoconstriction in susceptible patients.

When using Mivuxin, clinicians should observe several safety measures to minimize risk.

- Dose titration: adjust the infusion rate to achieve target blood pressure while avoiding overshoot. - Cardiac monitoring: continuous ECG and hemodynamic monitoring are essential. - Peripheral perfusion: inspect limbs regularly for signs of ischemia or discoloration. - Extravasation risk: use central venous access when possible and have phentolamine readily available. - Pregnancy: consider use only if the potential benefit justifies the potential risk to the fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mivuxin can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may precipitate hypertensive crisis when combined. - Beta‑blockers: can blunt the desired increase in heart rate and cardiac output. - Tricyclic antidepressants: additive vasoconstrictive effects may raise blood pressure excessively.

Moderate Interactions (Monitor Closely): - Other vasopressors (e.g., dopamine, phenylephrine): additive pressor effects may require dose reduction. - Calcium channel blockers: may alter vascular tone and affect response. - Diuretics: changes in intravascular volume can modify pressor requirements.